Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

140 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Expansion of Stem Cell-Like CD4+ Memory T Cells during Acute HIV-1 Infection Is Linked to Rapid Disease Progression.
Pušnik J, Eller MA, Tassaneetrithep B, Schultz BT, Eller LA, Nitayaphan S, Kosgei J, Maganga L, Kibuuka H, Alter G, Michael NL, Robb ML, Streeck H. Pušnik J, et al. Among authors: nitayaphan s. J Virol. 2019 Jun 28;93(14):e00377-19. doi: 10.1128/JVI.00377-19. Print 2019 Jul 15. J Virol. 2019. PMID: 31043532 Free PMC article. Clinical Trial.
Human immunodeficiency virus type 1 primary isolate neutralization resistance is associated with the syncytium-inducing phenotype and lower CD4 cell counts in subtype CRF01_AE-infected patients.
Polonis VR, de Souza MS, Darden JM, Chantakulkij S, Chuenchitra T, Nitayaphan S, Brown AE, Robb ML, Birx DL. Polonis VR, et al. Among authors: nitayaphan s. J Virol. 2003 Aug;77(15):8570-6. doi: 10.1128/jvi.77.15.8570-8576.2003. J Virol. 2003. PMID: 12857927 Free PMC article.
Molecular epidemiology of HIV Type 1 in preparation for a Phase III prime-boost vaccine trial in Thailand and a new approach to HIV Type 1 genotyping.
Watanaveeradej V, Benenson MW, Souza MD, Sirisopana N, Nitayaphan S, Tontichaivanich C, Amphaipit R, Renzullo PO, Brown AE, McNeil JG, Robb ML, Birx DL, Tovanabutra S, Carr JK, McCutchan FE. Watanaveeradej V, et al. Among authors: nitayaphan s. AIDS Res Hum Retroviruses. 2006 Aug;22(8):801-7. doi: 10.1089/aid.2006.22.801. AIDS Res Hum Retroviruses. 2006. PMID: 16910837 Clinical Trial.
Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand.
Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, Premsri N, Namwat C, de Souza M, Adams E, Benenson M, Gurunathan S, Tartaglia J, McNeil JG, Francis DP, Stablein D, Birx DL, Chunsuttiwat S, Khamboonruang C, Thongcharoen P, Robb ML, Michael NL, Kunasol P, Kim JH; MOPH-TAVEG Investigators. Rerks-Ngarm S, et al. Among authors: nitayaphan s. N Engl J Med. 2009 Dec 3;361(23):2209-20. doi: 10.1056/NEJMoa0908492. Epub 2009 Oct 20. N Engl J Med. 2009. PMID: 19843557 Free article. Clinical Trial.
Immune-correlates analysis of an HIV-1 vaccine efficacy trial.
Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD, Alam SM, Evans DT, Montefiori DC, Karnasuta C, Sutthent R, Liao HX, DeVico AL, Lewis GK, Williams C, Pinter A, Fong Y, Janes H, DeCamp A, Huang Y, Rao M, Billings E, Karasavvas N, Robb ML, Ngauy V, de Souza MS, Paris R, Ferrari G, Bailer RT, Soderberg KA, Andrews C, Berman PW, Frahm N, De Rosa SC, Alpert MD, Yates NL, Shen X, Koup RA, Pitisuttithum P, Kaewkungwal J, Nitayaphan S, Rerks-Ngarm S, Michael NL, Kim JH. Haynes BF, et al. Among authors: nitayaphan s. N Engl J Med. 2012 Apr 5;366(14):1275-86. doi: 10.1056/NEJMoa1113425. N Engl J Med. 2012. PMID: 22475592 Free PMC article.
The Thai phase III trial (RV144) vaccine regimen induces T cell responses that preferentially target epitopes within the V2 region of HIV-1 envelope.
de Souza MS, Ratto-Kim S, Chuenarom W, Schuetz A, Chantakulkij S, Nuntapinit B, Valencia-Micolta A, Thelian D, Nitayaphan S, Pitisuttithum P, Paris RM, Kaewkungwal J, Michael NL, Rerks-Ngarm S, Mathieson B, Marovich M, Currier JR, Kim JH; Ministry of Public Health–Thai AIDS Vaccine Evaluation Group Collaborators. de Souza MS, et al. Among authors: nitayaphan s. J Immunol. 2012 May 15;188(10):5166-76. doi: 10.4049/jimmunol.1102756. Epub 2012 Apr 23. J Immunol. 2012. PMID: 22529301 Free PMC article. Clinical Trial.
Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials.
Montefiori DC, Karnasuta C, Huang Y, Ahmed H, Gilbert P, de Souza MS, McLinden R, Tovanabutra S, Laurence-Chenine A, Sanders-Buell E, Moody MA, Bonsignori M, Ochsenbauer C, Kappes J, Tang H, Greene K, Gao H, LaBranche CC, Andrews C, Polonis VR, Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Self SG, Berman PW, Francis D, Sinangil F, Lee C, Tartaglia J, Robb ML, Haynes BF, Michael NL, Kim JH. Montefiori DC, et al. Among authors: nitayaphan s. J Infect Dis. 2012 Aug 1;206(3):431-41. doi: 10.1093/infdis/jis367. Epub 2012 May 25. J Infect Dis. 2012. PMID: 22634875 Free PMC article. Clinical Trial.
Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144.
Robb ML, Rerks-Ngarm S, Nitayaphan S, Pitisuttithum P, Kaewkungwal J, Kunasol P, Khamboonruang C, Thongcharoen P, Morgan P, Benenson M, Paris RM, Chiu J, Adams E, Francis D, Gurunathan S, Tartaglia J, Gilbert P, Stablein D, Michael NL, Kim JH. Robb ML, et al. Among authors: nitayaphan s. Lancet Infect Dis. 2012 Jul;12(7):531-7. doi: 10.1016/S1473-3099(12)70088-9. Epub 2012 May 30. Lancet Infect Dis. 2012. PMID: 22652344 Free PMC article. Clinical Trial.
140 results